Japanese pharmaceutical company Astellas has been a significant player in China’s healthcare market for three decades. Committed to improving patient access to innovative medicines, Astellas has deepened its partnerships with local companies, aiming to bring cutting-edge treatments to people across China.
Recently, Claus Zieler, the chief commercial officer of Astellas, spoke with CGTN’s Wang Tianyu about the rapid advancements in China’s pharmaceutical landscape. “China has made remarkable strides in accelerating the approval of new medicines,” Zieler noted. “This progress not only benefits patients in China but also contributes to global health innovation.”
Zieler highlighted how the evolving regulatory environment in China has fostered greater affordability and availability of essential medicines. By streamlining approval processes and encouraging innovation, China is setting a new standard in the pharmaceutical industry.
Astellas’ commitment to collaboration with Chinese companies underscores the importance of global partnerships in addressing healthcare challenges. “By working together, we can ensure that innovative treatments are accessible to those who need them most,” Zieler said.
As China continues to evolve its healthcare system, companies like Astellas remain dedicated to supporting these efforts, reinforcing the shared goal of improving patient lives through medical innovation.
Reference(s):
cgtn.com
